FISH in Triple-negative Breast Cancer: A Possible Strategy for the Future?

Elisa Rigon; Chiara Saggia; Valentina Rossi; Silvia Genestroni; Erica Gaudino; Paola Campisi; Claudia Veggiani; Renzo Luciano Boldorini; Oscar Alabiso


Future Oncol. 2015;11(7):1023-1026. 

In This Article


Based on the data collected until today, we need a better definition of TNBC and a more clear understanding of its heterogeneity; this is fundamental to help develop new targeted therapies that could be effective in this population. Moreover, it is important to identify new predictive markers, as they are extremely useful to understand the mechanism of action of drugs and to identify TNBC patients who could benefit from specific therapies. Given the heterogeneity of TNBCs, more biomarkers or even entire predictive pathways might be necessary to predict the benefits from new targeted drugs.[16]

Oncologists and pathologists should make every effort in the identification of this small subset of patients with breast cancer, because the lack of recognition of HER2 overexpression and therefore the exclusion of anti-HER2 agents from the therapy decreases disease-free survival and OS of these patients.

As a concluding remark, FISH assay in TNBCs could produce drastic changes in clinical practice; we hope that this method can soon become a standard and can be also extended to hormone-responsive breast cancers.